Diacerein, Oral inhibition of interleukin-1 in the treatment of osteoarthritis

The current COVID-19 pandemy impacts daily lives globally. As the crisis continues to evolve, it also shifts our ways of working and thinking. We at TRB are working hard to maintain our products and services and continue to make them available as we do during “normal times”.

Presentation of TRB Swiss plant based in Vouvry.

We have developed the VISMED® range of lubricant eye drops consisting in hypo-osmolar sodium hyaluronate solutions indicated for the treatment of symptoms and signs of dry eye

Presentation of the Vismed range for dry eye from TRB Chemedica

TRB Chemedica researches, develops, manufactures and markets different molecules to treat osteoarthritis-induced pain such as hyaluronic acid-based products and diacerein. OSTENIL® range consists of sodium hyaluronate-containing products with different formulations and has been developed to improve osteoarthritis patients’ symptoms and joint function after intra-articular injection.

TRB Chemedica has pioneered the use of sodium hyaluronate obtained by biofermentation, with a focus on patient safety and improved clinical outcomes.Due to its high biocompatibility and common presence in the extracellular matrix of tissues, hyaluronic acid has gained popularity during recent decades and is now used in many fields of medicine, such as orthopaedics, rheumatology, ophthalmology, tissue repair...

We are thrilled to announce the launch of our new Swiss website available in four different languages (German, French, Italian and English).